Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$730.96K-$730.96KN/M vs Q3 2023 EPS Diluted$0.00$0.00— vs Q3 2023 Operating Income-$813,196N/M Operating Cash Flowderived-$720,438N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end